aurinia pharmaceuticals inc. - AUPH
AUPH
Close Chg Chg %
9.04 -0.01 -0.11%
Closed Market
9.03
-0.01 (0.11%)
Volume: 1.58M
Last Updated:
Dec 20, 2024, 4:00 PM EDT
Company Overview: aurinia pharmaceuticals inc. - AUPH
AUPH Key Data
| Open $8.95 | Day Range 8.92 - 9.23 |
| 52 Week Range 4.71 - 10.67 | Market Cap $1.29B |
| Shares Outstanding 143.18M | Public Float 128.77M |
| Beta 1.41 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.16 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.56M |
AUPH Performance
| 1 Week | -3.63% | ||
| 1 Month | 1.92% | ||
| 3 Months | 25.42% | ||
| 1 Year | -1.85% | ||
| 5 Years | -54.12% |
AUPH Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
6
Full Ratings ➔
About aurinia pharmaceuticals inc. - AUPH
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
AUPH At a Glance
Aurinia Pharmaceuticals, Inc.
14315 – 118 Avenue
Edmonton, Alberta T5L 4S6
| Phone | 1-250-744-2487 | Revenue | 175.51M | |
| Industry | Biotechnology | Net Income | -78,020,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 30.951% | |
| Fiscal Year-end | 12 / 2024 | Employees | 300 | |
| View SEC Filings |
AUPH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.337 |
| Price to Book Ratio | 3.421 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -14.44 |
| Enterprise Value to Sales | 5.896 |
| Total Debt to Enterprise Value | 0.094 |
AUPH Efficiency
| Revenue/Employee | 585,043.333 |
| Income Per Employee | -260,066.667 |
| Receivables Turnover | 7.286 |
| Total Asset Turnover | 0.345 |
AUPH Liquidity
| Current Ratio | 5.503 |
| Quick Ratio | 4.989 |
| Cash Ratio | 4.541 |
AUPH Profitability
| Gross Margin | 91.939 |
| Operating Margin | -47.468 |
| Pretax Margin | -44.139 |
| Net Margin | -44.453 |
| Return on Assets | -15.314 |
| Return on Equity | -19.919 |
| Return on Total Capital | -16.406 |
| Return on Invested Capital | -17.883 |
AUPH Capital Structure
| Total Debt to Total Equity | 25.825 |
| Total Debt to Total Capital | 20.525 |
| Total Debt to Total Assets | 17.809 |
| Long-Term Debt to Equity | 21.698 |
| Long-Term Debt to Total Capital | 17.245 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Aurinia Pharmaceuticals Inc. - AUPH
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 50.12M | 45.61M | 134.03M | 175.51M | |
Sales Growth
| +15,660.38% | -9.00% | +193.89% | +30.95% | |
Cost of Goods Sold (COGS) incl D&A
| - | 3.19M | 5.66M | 14.15M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 1.37M | 2.76M | 2.71M | 11.65M | |
Depreciation
| 82.00K | 663.00K | 629.00K | 606.00K | |
Amortization of Intangibles
| 1.29M | 2.10M | 2.08M | 11.04M | |
COGS Growth
| - | - | +77.61% | +149.79% | - |
Gross Income
| - | 42.42M | 128.37M | 161.37M | |
Gross Income Growth
| - | - | +202.64% | +25.71% | - |
Gross Profit Margin
| - | +93.01% | +95.77% | +91.94% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 146.23M | 222.58M | 241.36M | 244.68M | |
Research & Development
| 50.33M | 51.14M | 44.99M | 49.64M | |
Other SG&A
| 95.90M | 171.44M | 196.37M | 195.04M | |
SGA Growth
| +94.92% | +52.21% | +8.44% | +1.37% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (97.48M) | (180.16M) | (112.99M) | (83.31M) | |
Non Operating Income/Expense
| (5.29M) | (45.00K) | 6.64M | 8.62M | |
Non-Operating Interest Income
| 1.52M | 529.00K | 5.12M | 17.00M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | 2.78M | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | 2.78M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (102.77M) | (180.21M) | (106.35M) | (77.47M) | |
Pretax Income Growth
| +16.92% | -75.34% | +40.98% | +27.16% | |
Pretax Margin
| -205.06% | -395.15% | -79.35% | -44.14% | |
Income Tax
| (94.00K) | 760.00K | 1.83M | 551.00K | |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| (94.00K) | 760.00K | 1.83M | 551.00K | |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (102.68M) | (180.97M) | (108.18M) | (78.02M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (102.68M) | (180.97M) | (108.18M) | (78.02M) | |
Net Income Growth
| +17.09% | -76.24% | +40.22% | +27.88% | |
Net Margin Growth
| -204.88% | -396.81% | -80.71% | -44.45% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (102.68M) | (180.97M) | (108.18M) | (78.02M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (102.68M) | (180.97M) | (108.18M) | (78.02M) | |
EPS (Basic)
| -0.8667 | -1.3988 | -0.7623 | -0.5447 | |
EPS (Basic) Growth
| +34.90% | -61.39% | +45.50% | +28.55% | |
Basic Shares Outstanding
| 118.47M | 129.37M | 141.91M | 143.24M | |
EPS (Diluted)
| -0.8667 | -1.3988 | -0.7623 | -0.5447 | |
EPS (Diluted) Growth
| +34.90% | -61.39% | +45.50% | +28.55% | |
Diluted Shares Outstanding
| 118.47M | 129.37M | 141.91M | 143.24M | |
EBITDA
| (96.11M) | (177.40M) | (110.29M) | (71.67M) | |
EBITDA Growth
| -28.66% | -84.58% | +37.83% | +35.02% | |
EBITDA Margin
| -191.77% | -388.99% | -82.29% | -40.83% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 10.836 | |
| Number of Ratings | 6 | Current Quarters Estimate | 0.016 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 0.026 | |
| Last Quarter’s Earnings | 0.10 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -0.54 | Next Fiscal Year Estimate | 0.572 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 5 | 2 | 5 | 5 |
| Mean Estimate | 0.02 | 0.11 | 0.03 | 0.57 |
| High Estimates | 0.16 | 0.11 | 0.22 | 0.69 |
| Low Estimate | -0.09 | 0.10 | -0.05 | 0.45 |
| Coefficient of Variance | 768.78 | 6.73 | 427.08 | 16.51 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 4 | 5 | 5 |
| OVERWEIGHT | 1 | 1 | 1 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Buy | Buy |
SEC Filings for Aurinia Pharmaceuticals Inc. - AUPH
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Aurinia Pharmaceuticals Inc. - AUPH
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 26, 2024 | Craig A. Johnson Director | 20,631 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Jeffrey Allen Bailey Director | 25,491 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Jeffrey Allen Bailey Director | 18,641 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Jill Leversage Director | 18,641 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Jill Leversage Director | 25,053 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | David R. W. Jaynee Director | 56,499 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Karen L. Smith Director | 24,807 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Karen L. Smith Director | 18,641 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | David R. W. Jaynee Director | 18,641 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Craig A. Johnson Director | 31,688 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Aug 9, 2024 | Scott Habig Chief Commercial Officer | 456,338 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.31 per share | 2,423,154.78 |
| May 23, 2024 | Brinda Balakrishnan Director | 17,523 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.74 per share | 100,582.02 |
| May 23, 2024 | Daniel G. Billen Director | 28,141 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.74 per share | 161,529.34 |
| May 23, 2024 | R. Hector MacKay-Dunn Director | 18,595 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.74 per share | 106,735.30 |
| May 3, 2024 | Aurinia Pharmaceuticals, Inc. | 133,627 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $4.94 per share | 660,117.38 |
| May 3, 2024 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $4.99 per share | 0.00 |
| May 3, 2024 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $4.94 per share | 0.00 |
| May 3, 2024 | Aurinia Pharmaceuticals, Inc. | 81,087 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $4.99 per share | 404,624.13 |
| May 3, 2024 | Aurinia Pharmaceuticals, Inc. | N/A | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $4.99 per share | 0.00 |
| May 3, 2024 | Aurinia Pharmaceuticals, Inc. | 7,601 | Redemption/retraction/cancellation/repurchase Non-derivative transaction at $4.99 per share | 37,928.99 |